ICPT - grabbed shares pre-market at $178.37 as they priced the offering. Now flush with a ton of cash and a mutual Phase3 FDA/Company trial design means much much easier approval ....
"$BIAD The potential for this one to tutn EPS + soon is there. Cash burn is now down to $70K/month and influx of $1M from Sysmex should be counted as either deferred revenue or current revenue. Because they actually received the cash in Q1, I'd say it will be recorded as current and with no debt, zero dilution, and cash burn of 70K/month, that will have a big impact on the fundamentals"
News 
Market Data 
Discover 
